You are given a text that consists of multiple sentences. Your task is to perform abstractive summarization on this text. Use your understanding of the content to express the main ideas and crucial details in a shorter, coherent, and natural sounding text.

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Emergent BioSolutions Inc. (Emergent or the Company) (NYSE: EBS) investors concerning the Companys possible violations of the federal securities laws. If you suffered a loss on your Emergent investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/emergent-biosolutions-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights. On March 31, 2021, The New York Times published an article reporting that in late February 2021, employees at Emergents Baltimore manufacturing plant mixed up ingredients of the different COVID-19 vaccines, contaminating up to 15 million doses of the Johnson & Johnson (J&J) vaccine forcing regulators to delay authorization of the plants production line. On April 1, 2021, the Associated Press reported on Emergents history of violations, noting that the U.S. Food and Drug Administration (FDA) has repeatedly cited Emergent for problems such as poorly trained employees, cracked vials and problems managing mold and other contamination in its facilities. On April 3, 2021, The New York Times reported that the Biden administration placed J&J in charge of Emergents Baltimore plant and prohibited it from producing the AstraZeneca vaccine, a setback for a Company that had touted its unique preparedness and proven manufacturing capabilities only months prior. On this news, the Companys stock price fell $14.29 per share, or over 15%, over two consecutive trading sessions to close at $78.62 per share on April 5, 2021. Follow us for updates on LinkedIn, Twitter, or Facebook. Whistleblower Notice: Persons with non-public information regarding Emergent should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@glancylaw.com. About GPM Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. ISS Securities Class Action Services has consistently ranked GPM in its annual SCAS Top 50 Report. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPMs nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPMs lawyers have handled cases covering a wide spectrum of corporate misconduct including cases involving financial restatements, internal control weaknesses, earnings management, fraudulent earnings guidance and forward looking statements, auditor misconduct, insider trading, violations of FDA regulations, actions resulting in FDA and DOJ investigations, and many other forms of corporate misconduct. GPMs attorneys have worked on securities cases relating to nearly all industries and sectors in the financial markets, including, energy, consumer discretionary, consumer staples, real estate and REITs, financial, insurance, information technology, health care, biotech, cryptocurrency, medical devices, and many more. GPMs past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barrons, Investors Business Daily, Forbes, and Money. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Answer: Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Emergent BioSolutions Inc. (EBS) on Behalf of Investors